Michelle A. Hurchla

BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1

Norihiko Watanabe, Maya Gavrieli, John R. Šedý et al. · Nature Immunology · 2003 · 863 citations

Lymphocyte Inhibitory Receptor, Autoimmune Disease, Immunology +7

B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator

John R. Šedý, Maya Gavrieli, Karen G. Potter et al. · Nature Immunology · 2004 · 615 citations

T Cell Activation, Adaptive Immune System, T-regulatory Cell +8

B and T Lymphocyte Attenuator Exhibits Structural and Expression Polymorphisms and Is Highly Induced in Anergic CD4+ T Cells

Michelle A. Hurchla, John R. Šedý, Maya Gavrielli et al. · The Journal of Immunology · 2005 · 177 citations · Full text

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects

Michelle A. Hurchla, Antonio García-Gómez, Mary C. Hornick et al. · Leukemia · 2012 · 143 citations · Full text

Epoxyketone-based Proteasome Inhibitors, Medicinal Chemistry, Bone-anabolic Activity +7

The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling

Xinming Su, Desiree H. Floyd, Alun D. Hughes et al. · Journal of Clinical Investigation · 2012 · 101 citations · Full text

Sclerostin, Osteoclast Function, Adenosine Diphosphate +24